Hsu Jason insider trades
Hsu Jason has filed 13 Form 4s with the SEC that we hold, all for Immix Biopharma, Inc. (IMMX), as Director. Across all of them we count 14 purchases worth $918.0K and 0 sales worth $0 reported on Form 4. None of these purchases or sales is dated in the last 12 months. The largest single trade was a purchase of 50,000 shares of Immix Biopharma, Inc. worth $250.0K, dated 2021-12-20. The first filing on our record is dated 2021-12-20 and the latest 2026-05-29.
Immix Biopharma, Inc. (IMMX)
| Trade date | Code | Shares | Value as filed | Filed |
|---|---|---|---|---|
| 2021-12-20 | P, purchase reported on Form 4 | 50,000 | $250.0K | 2021-12-20 |
| 2023-09-08 | P, purchase reported on Form 4 | 10,000 | $25.3K | 2023-09-12 |
| 2023-09-11 | P, purchase reported on Form 4 | 25,000 | $72.2K | 2023-09-18 |
| 2023-09-12 | P, purchase reported on Form 4 | 30,000 | $84.9K | 2023-09-18 |
| 2023-09-14 | P, purchase reported on Form 4 | 10,000 | $25.8K | 2023-09-18 |
| 2023-09-15 | P, purchase reported on Form 4 | 7,000 | $17.4K | 2023-09-18 |
| 2023-12-08 | P, purchase reported on Form 4 | 25,000 | $122.0K | 2023-12-12 |
| 2023-12-11 | P, purchase reported on Form 4 | 31,000 | $144.8K | 2023-12-12 |
| 2024-07-18 | P, purchase reported on Form 4 | 3,200 | $6.6K | 2024-07-31 |
| 2024-07-24 | P, purchase reported on Form 4 | 6,000 | $12.9K | 2024-07-31 |
| 2024-08-21 | P, purchase reported on Form 4 | 15,000 | $33.5K | 2024-08-26 |
| 2024-08-22 | P, purchase reported on Form 4 | 8,100 | $18.2K | 2024-08-26 |
| 2024-12-20 | P, purchase reported on Form 4 | 7,700 | $16.7K | 2024-12-26 |
| 2024-12-23 | P, purchase reported on Form 4 | 40,000 | $87.6K | 2024-12-26 |
Counted from the Form 4 filings this reporting owner (SEC CIK 1895035) filed on EDGAR. Values are the transaction values as filed. See every filing on EDGAR, or browse insider buying and today's insider purchases.
Source: U.S. Securities and Exchange Commission (EDGAR) and other official
government data · Updated 2026-10-12 ·
For informational purposes only, not investment advice.
Privacy · Terms